Peptide Side Effects: What to Know Before Starting

Key Takeaways

• GLP-1 class peptides: Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — are the most commonly reported adverse events in clinical trials. Cholelithiasis is a monitored rare-but-serious event.
• Evidence quality matters: FDA-approved peptide drugs have defined adverse event profiles from large trials. Unregulated research peptides have side effect profiles that cannot be systematically characterized.
• Injection site reactions: Local redness, swelling, and discomfort at the injection site are common with subcutaneous peptide administration; proper technique and rotation reduce incidence.
• Unregulated risk: Documented cases of severe harm from online-purchased research peptides illustrate that unknown side effect profiles are not equivalent to no side effects.
• Monitoring: Baseline bloodwork before initiating any peptide compound — and follow-up testing at appropriate intervals — is commonly used to detect and manage adverse effects.

Side Effects of GLP-1 Receptor Agonist Peptides

The GLP-1 receptor agonist class — including semaglutide, liraglutide, and tirzepatide — is among the most extensively studied peptide categories in terms of side effects. The clinical trial database for these compounds spans hundreds of thousands of patient-years of exposure.

Gastrointestinal effects: the primary adverse event category

Nausea, vomiting, diarrhea, and constipation are the most consistently reported adverse events across GLP-1 class peptides. A network meta-analysis by Sun and colleagues, published in Diabetes Technology and Therapeutics in 2015, established GI adverse events as dominant profile across GLP-1 receptor agonists as a class. A 2024 meta-analysis by Rivera and colleagues, drawing on 57,911 participants across 23 randomized controlled trials, confirmed GI effects as primary adverse event category for semaglutide, characterizing the overall safety profile as favorable within the context of these well-characterized side effects. In the STEP 1 trial by Wilding and colleagues, published in the New England Journal of Medicine in 2021 with 1,961 participants, the most commonly reported adverse events were nausea, diarrhea, constipation, and vomiting, accompanying 14.9% mean weight reduction versus 2.4% with placebo at 68 weeks.

The SELECT trial by Lincoff and colleagues, published in the New England Journal of Medicine in 2023, enrolled 17,604 participants and reported that adverse-event-driven discontinuation occurred in 16.6% of semaglutide participants versus 8.2% in the placebo group, reflecting the real-world tolerability burden of GI effects even as the trial reported a 20% reduction in the composite cardiovascular endpoint versus placebo over a median follow-up of approximately 40 months. This trade-off between tolerability and efficacy is central to prescribing decisions for GLP-1 class agents. A 2021 review by Smits and Van Raalte in Frontiers in Endocrinology characterized these GI side effects as mild to moderate in severity, most prominent during dose escalation, and typically diminishing as dose is maintained.

Tirzepatide-specific side effect rates

Tirzepatide, the dual GIP/GLP-1 agonist, has an overlapping but distinct side effect profile. A meta-analysis by Kommu and colleagues, published in Obesity Reviews in 2025, found tirzepatide increased odds of nausea, vomiting, diarrhea (OR 4.26, 8.35, and 3.57 respectively) compared with placebo in patients without diabetes (3 RCTs, n=3,901). An analysis by Tan and colleagues, published in the International Journal of Obesity in 2023, examined approximately 5,800 patients and characterized the overall safety profile as consistent with class-wide GI side effects, with no unexpected serious adverse event signals versus placebo in the analyzed population. A meta-analysis of 10 tirzepatide trials by Mishra and colleagues, published in the Journal of the Endocrine Society in 2023, found serious complications at or below 1% across all doses — establishing that while GI effects are common, serious adverse events are rare.

Cholelithiasis and hepatobiliary events

Gallstone formation (cholelithiasis) is a monitored rare-but-serious adverse event with GLP-1 class peptides. A meta-analysis by Monami and colleagues, published in Diabetes, Obesity and Metabolism in 2017 and covering 113 randomized controlled trials, found GLP-1 receptor agonists carried increased cholelithiasis risk, no pancreatitis signal, and no significant increase in pancreatic cancer risk. A review by Ghusn and colleagues, published in Obesity Pillars in 2024, noted rare gallbladder, pancreatitis, and anesthesia concerns. Hepatobiliary monitoring and patient education about gallstone symptoms are commonly part of prescribing practice for GLP-1 class agents.

Thyroid cancer: the rodent signal and human data

Rodent carcinogenicity studies for GLP-1 receptor agonists observed thyroid C-cell tumors, leading to a class-wide FDA boxed warning. A large Scandinavian cohort study by Pasternak and colleagues, published in the BMJ in 2024 and following more than 145,000 patients, found no substantially increased thyroid cancer risk over a mean 3.9-year follow-up. The clinical significance of the rodent signal has not been confirmed in human populations at current follow-up lengths, but the boxed warning remains on all labeled GLP-1 receptor agonist products and pharmacovigilance continues. Ruggiero and colleagues, publishing in the European Journal of Pharmacology in 2025, conducted a pharmacovigilance analysis of two GLP-1 peptides — finding liraglutide had higher pancreatitis and thyroid tumor reporting rates while semaglutide had more vomiting and abdominal pain reports — illustrating that side effect profiles differ even within the same drug class.

Kidney function: no renal safety signal in trial data

Concerns about kidney side effects from GLP-1 class peptides are not supported by the available trial data. A meta-analysis by Mendonça and colleagues, published in the Clinical Journal of the American Society of Nephrology in 2024 and covering 68,572 patients, reported a 16% reduction in worsening kidney function versus placebo in pooled trial data, with no renal safety signal identified — an effect directionally opposite to a renal safety concern.

Side Effects of Growth Hormone-Releasing Peptides

Growth hormone-releasing peptides (GHRPs) and related GH secretagogues have a substantially smaller human safety database than GLP-1 class agents. The single FDA-approved GHRH analog in this broader class is tesamorelin; the rest are either compounded preparations or investigational compounds.

Tesamorelin: the FDA-approved GHRH analog

Tesamorelin (Egrifta) is the only FDA-approved GHRH analog, indicated specifically for HIV-associated lipodystrophy. Its labeled adverse events include injection site reactions, glucose intolerance, fluid retention, and arthralgia. Tesamorelin is classified as a biologic under the Biologics Price Competition and Innovation Act and cannot be compounded under 503A — only the FDA-approved product is legally available.

CJC-1295 and related GHRPs: limited data and adverse PCAC recommendation

A clinical study by Teichman and colleagues, published in the Journal of Clinical Endocrinology and Metabolism in 2006, reported no serious adverse events at doses of 30 to 60 mcg/kg in the small study population, though the authors characterized the safety data as early and limited. The study was not designed or powered to establish CJC-1295 safety at the regulatory level, and the April 22, 2026 FDA Pharmacy Compounding Advisory Committee recommended against adding CJC-1295 and ipamorelin to the 503A bulk drug substances list citing inadequate safety characterization. A review by Sigalos and Pastuszak, published in Sexual Medicine Reviews in 2018, noted few serious adverse events in short-term studies but identified an unfavorable profile in patients with congestive heart failure and emphasized the absence of long-term safety data. Short-term tolerability in small trials does not constitute a full safety evaluation for clinical use.

Adverse Events Reported from Self-Administration of Non-FDA-Approved Peptide Compounds

Compounds sold labeled "for research use only" — including BPC-157, TB-500, and similar peptides — do not have adequate human safety data to characterize a side effect profile. This is not a statement that they are safe; it is a statement that the data needed to evaluate safety does not exist at clinical-evidence standards.

BPC-157: the limits of the current evidence and restricted compounding status

As of April 2026, BPC-157 is classified as an FDA Category 2 bulk drug substance with restricted 503A compounding access; it is not available through most licensed compounding pharmacies. A review by McGuire and colleagues, published in Current Reviews in Musculoskeletal Medicine in 2025, identified 36 BPC-157 studies, 1 clinical, with no clinical safety data, and concluded clinicians should exercise caution. A 2025 pilot study by Lee and colleagues, published in Alternative Therapies in Health and Medicine, reported no adverse effects across cardiac, hepatic, renal, thyroid, and glucose biomarkers in two healthy adults receiving intravenous BPC-157 over a short observation period. An N of 2 does not permit any inference about adverse event rates. Most BPC-157 research consists of rodent models, which do not reliably predict human side effect profiles.

Immunogenicity: a peptide-specific adverse event category

Immunogenicity — the formation of anti-drug antibodies in response to a therapeutic peptide — is a peptide-specific adverse event category with potentially serious consequences including hypersensitivity reactions, loss of efficacy, and cross-reactivity with endogenous proteins. Achilleos and colleagues, writing in the Journal of Peptide Science in 2025, reviewed immunogenicity as central safety concern in peptide therapeutics and the importance of assessing drug impurities and anti-drug antibody responses. Naik and colleagues, publishing in the Journal of Clinical Pharmacology in 2025, found that even among 53 FDA-approved peptide drug labels, only 40% included immunogenicity reporting — illustrating that this category of side effects is under-characterized even for approved compounds, and essentially uncharacterized for research peptides.

Manufacturing quality-driven side effects

Beyond pharmacological side effects, impurity-driven adverse events represent an independent risk category for any peptide product not manufactured under pharmaceutical-grade quality control. D'Hondt and colleagues, in their 2014 analysis published in the Journal of Pharmaceutical and Biomedical Analysis, reviewed contamination sources in peptide synthesis including amino acid deletion sequences, oxidation products, and diketopiperazine formation — each capable of producing adverse effects unrelated to the intended compound's mechanism.

Documented severe harm: the Melanotan II case

Melanotan II is not FDA-approved for any indication and is not discussed here in a therapeutic context; it is included solely to illustrate documented harm from unregulated self-administration of an online-purchased compound. Nelson and colleagues published a 2012 case report in Clinical Toxicology documenting a patient who self-administered Melanotan II — an unregulated synthetic tanning peptide purchased online — and developed severe rhabdomyolysis (muscle breakdown), requiring intensive care unit admission for acute kidney dysfunction and systemic toxicity. The case demonstrates that the combination of uncertain product identity, uncontrolled dosing, and lack of medical supervision can produce serious adverse outcomes independent of whether the compound's intended mechanism is intrinsically harmful.

Injection Site Reactions and Route-Specific Effects

Subcutaneous injection — the delivery route for GLP-1 agonists, GH-releasing peptides, and most research peptides — carries route-specific adverse events that are distinct from systemic pharmacological effects. Local reactions including redness, swelling, bruising, induration, and discomfort at the injection site are among the most commonly reported adverse events for any injectable peptide compound.

A 2021 review by Zou in the Journal of Controlled Release found that approximately 50% of peptide therapeutics exhibit injection-site-dependent pharmacokinetics, meaning that the choice of injection site and technique directly affects drug absorption and plasma exposure — not just local tolerability. An analysis by Esposito and colleagues, published in Xenobiotica in 2022, described the subcutaneous catabolism of peptides before they reach systemic circulation and how local tissue environment affects this process — providing mechanistic context for why injection site management matters beyond pain reduction.

Monitoring Biomarkers for Side Effect Detection

Baseline bloodwork before initiating any peptide compound — and follow-up testing at appropriate intervals — is commonly used to detect and manage adverse effects. The specific markers monitored depend on the compound category. Superpower's biomarker testing establishes baseline reference points for general health assessment and is not designed or marketed as a monitoring service for non-FDA-approved compounds. Readers should not infer that baseline testing is a step toward initiating any specific compound discussed in this article.

• HbA1c and fasting glucose: Primary efficacy and safety markers for metabolic peptides. Baseline HbA1c and glucose make any glycemic change attributable to the compound rather than background metabolic drift.
• Fasting insulin: Characterizes insulin sensitivity before any metabolic intervention. Baseline fasting insulin contextualizes the glycemic response to GLP-1 class therapy.
• Lipid panel: Monitored during GLP-1 agonist therapy for cholelithiasis risk and lipid effects. Pre-treatment triglycerides and lipid fractions provide the comparison point.
• IGF-1: The primary marker for GH axis activity. Relevant for monitoring the pharmacological effect and safety context of GH-releasing peptides. IGF-1 monitoring is standard with tesamorelin and related compounds.
• hs-CRP: Systemic inflammatory marker. Relevant for compounds studied in anti-inflammatory contexts; also monitors for any unexpected inflammatory response. High-sensitivity CRP is a sensitive baseline measure.
• eGFR (kidney function): Renal clearance affects peptide pharmacokinetics, and kidney function is monitored for compounds with renal elimination. An eGFR baseline is the starting point for any renal safety assessment.
• Liver enzymes (ALT, AST): Hepatic function baseline standard for any compound with hepatic processing. Elevation in liver enzymes can indicate hepatocellular stress independent of the primary compound's mechanism.

The inflammation and muscle recovery biomarker guide covers the inflammatory and tissue-stress markers most relevant to monitoring injectable peptide effects.

When Side Effect Questions Require Clinical Evaluation

Persistent GI symptoms, unexpected changes in bloodwork, injection site reactions that do not resolve, or any systemic symptom that develops after initiating a peptide compound warrant evaluation by a licensed healthcare provider. The appropriate response to an unexpected adverse effect is not dose adjustment based on online guidance — it is clinical assessment with objective data.

The principle that biology should be understood before it is acted upon is foundational to Superpower's approach to preventive health. Establishing a baseline before any compound is initiated means that when something changes, there is objective data to interpret what changed, by how much, and in what direction — context that is absent without that prior measurement.

IMPORTANT SAFETY INFORMATION

This article discusses peptides as a broad category, including both FDA-approved medications and compounds that are not FDA-approved for any human use. Not all peptides discussed carry the same evidence base or safety profile. Superpower Health does not prescribe, sell, or facilitate access to peptide compounds that are not FDA-approved for human use.

FDA-approved peptide medications are prescription drugs that must be obtained through a licensed healthcare provider. Non-approved research peptides, often sold labeled "for research use only," are not regulated for human safety, efficacy, or manufacturing quality. Products purchased through unregulated channels may contain incorrect doses, contaminants, or misidentified compounds.

Current regulatory status of specific compounds discussed: As of April 2026, BPC-157 and TB-500 are classified as FDA Category 2 bulk drug substances with restricted 503A compounding access. On April 22, 2026, the FDA Pharmacy Compounding Advisory Committee recommended against including CJC-1295 and ipamorelin on the 503A bulk drug substances list, citing inadequate safety characterization. Thymosin alpha-1 does not hold FDA approval for any indication in the United States. Tesamorelin is the only FDA-approved GHRH analog (indicated for HIV-associated lipodystrophy) and is a BPCIA biologic that cannot be compounded under 503A.

This content is not a substitute for medical advice, diagnosis, or treatment. If you are considering any peptide-based compound, consult a licensed healthcare provider before proceeding. Individual health conditions, medications, and organ function affect both suitability and response.

For information about the specific FDA-approved peptide medications discussed in this article (semaglutide, liraglutide, tirzepatide, tesamorelin, bremelanotide), visit dailymed.nlm.nih.gov. DailyMed does not contain entries for non-FDA-approved compounds such as BPC-157, CJC-1295, TB-500, or thymosin alpha-1, because those compounds do not have FDA-approved labeling. For FDA guidance on compounded peptides and bulk drug substance classifications, visit the FDA's compounding resource center.

Disclaimer: This page discusses peptides as a category, including both FDA-approved medications and compounds not approved for human use. Superpower Health offers tirzepatide. Other compounds mentioned are not available through Superpower. See individual compound pages for availability and regulatory status. This content is for educational and informational purposes only.